Vivo Bio Tech: Proceedings /Outcome of the 39 th Annual General Meeting (AGM) of the Company held on September 30, 2026
Vivo Bio Tech (VIVOBIOT) filed a disclosure titled "Proceedings /Outcome of the 39 th Annual General Meeting (AGM) of the Company held on September 30, 2026". The company is valued at about ₹37.86 crore.
What happened
Vivo Bio Tech (VIVOBIOT) filed a disclosure with the exchanges on 30 September 2026 at 06:57 PM titled "Proceedings /Outcome of the 39 th Annual General Meeting (AGM) of the Company held on September 30, 2026".
Company snapshot
Vivo Bio Tech is a micro-cap company, with a market value of about ₹37.86 crore.
The stock last traded at ₹17.06, against a 52-week range of ₹15.51–₹20.44 (16.5% below the high).
Before this filing the shares had moved −5.8% over the month. Average daily turnover over the last 20 sessions was about ₹0.04 crore.
Promoters held 30.62% at the end of Q1 FY27, down 4.81% points from the previous quarter.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 12 | 1.4 | 0.76 |
| Q2 FY26 | 13 | 0.9 | 0.45 |
| Q3 FY26 | 13 | 1.3 | 0.57 |
| Q4 FY26 | 14 | -5.4 | -2.65 |
| Q1 FY27 | 14 | 0.2 | 0.08 |
What history shows
This is not the company's first management change disclosure: BCEIE has 8 earlier filings of this kind on record since May 2026.
Market-wide, 3,833 management change filings with an impact score of 50 or more saw an average next-day move of −0.1%, with 44% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- The appointment of a successor and any change in strategy or guidance.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.